Mumbai, India – Pharmaceutical giant Cipla has confirmed that its wholly-owned US subsidiary, InvaGen Pharmaceuticals Inc., received one inspectional observation in Form 483 from the United States Food and Drug Administration (USFDA). The observation followed a routine current Good Manufacturing Practices (cGMP) inspection conducted at InvaGen's manufacturing facility in Central Islip, Long Island, New York.
The inspection by the USFDA took place between July 13, 2026, and July 17, 2026. Following its conclusion, the company was issued a single Form 483, which lists conditions or practices that may violate the U.S. Food, Drug, and Cosmetic Act.
Cipla has stated its commitment to addressing the observation comprehensively. In an official communication, the company affirmed it would work closely with the USFDA to resolve the issue within the stipulated timeframe.
Investors reacted to the news with Cipla shares closing 0.77% lower at Rs 1418.40 on Friday, down from its previous close of Rs 1429.45. The company's market capitalization also saw a slight dip, settling at Rs 1.14 lakh crore. A total of 0.29 lakh shares were traded during Friday's session, amounting to a turnover of Rs 4.12 crore.
Impact on Operations and Future Outlook
While a single Form 483 observation typically indicates minor issues, pharmaceutical companies are required to respond to the USFDA with a corrective action plan. Cipla's prompt commitment to addressing the observation underscores its dedication to maintaining high manufacturing standards and ensuring compliance with international regulatory requirements.
Cipla's Global Footprint
As a prominent global pharmaceutical company, Cipla has a significant presence in the US market through its subsidiaries like InvaGen Pharmaceuticals. Ensuring regulatory compliance at its manufacturing sites is crucial for its continued operations and product approvals in the United States, a key market for generic and specialty medicines.